Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 31% Improvement Relative Risk Ventilation 10% c19early.org/e Aidouni et al. Aspirin for COVID-19 ICU PATIENTS Favors aspirin Favors control
The impact of asprin use on the outcome of patients admitted to the intensive care unit with COVID-19 infection
Aidouni et al., Research Square, doi:10.21203/rs.3.rs-2313880/v1 (Preprint)
Aidouni et al., The impact of asprin use on the outcome of patients admitted to the intensive care unit with COVID-19.., Research Square, doi:10.21203/rs.3.rs-2313880/v1 (Preprint)
Nov 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective study of 1,124 COVID-19 ICU patients, showing lower mortality with aspirin treatment.
risk of death, 30.9% lower, HR 0.69, p = 0.003, treatment 202 of 712 (28.4%), control 165 of 412 (40.0%), NNT 8.6, adjusted per study, multivariable, Cox proportional hazards.
risk of mechanical ventilation, 9.6% lower, RR 0.90, p = 0.33, treatment 189 of 712 (26.5%), control 121 of 412 (29.4%), NNT 35.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Aidouni et al., 30 Nov 2022, prospective, Morocco, preprint, mean age 64.0, 6 authors, study period March 2020 - March 2022.
Contact: aminbouchlarhem63@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: The impact of asprin use on the outcome of patients admitted to the intensive care unit with COVID-19 infection Ghizlane El Aidouni (  aminbouchlarhem63@gmail.com ) Mohammed I st University Amine Bouchlarhem Mohammed I st University Houssam Bkiyar Mohammed I st University Nabila Ismaili Mohammed I st University Noha El Ouafi Mohammed I st University Brahim housni Mohammed I st University Research Article Keywords: Covid-19, Aspirin, Mortality, Thrombo-embolic events Posted Date: November 30th, 2022 DOI: https://doi.org/10.21203/rs.3.rs-2313880/v1 License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/14 Abstract Background Our objective in this study is to know the impact of the use of asprin in anti-aggregation dose on the evolution during hospitalization of patients admitted in intensive care unit for a severe infection by SARSCOV-2. Methods We conducted a prospective study of patients admitted to our department with severe COVID-19 infection during the period between March 2020 and March 2022, analyzing the difference between the placebo group and the aspirin group on the primary endpoint of all-cause hospital mortality and the composite secondary endpoint of use of mechanical ventilation and thromboembolic events. Results Out of 1124 patients included, 32.6% died, with a protective effect of aspirin against placebo (Hazardratio = 0.691, p = 0.003), for thrombo-embolic complications, 104 events were observed, with a protective effect of aspirin (Hazard-Ratio = 0.448 and p = 0.001), finally regarding mechanical ventilation, there was no remarkable benefit on our sample. Conclusion Given the divergence of results of studies published in the literature, the availability of results of large randomized controlled trials is a necessity.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit